Dyadic Expands Global Presence with Participation in Key Industry Events

by B2i | Oct 9, 2024 | Press Releases

JUPITER, Fla., Oct. 09, 2024 — Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the large-scale, efficient manufacturing of proteins for human and animal vaccines, therapeutics, and...

Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference

by B2i | Sep 23, 2024 | Press Releases

JUPITER, Fla., Sept. 23, 2024 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient, large-scale manufacture of...

Dyadic Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

by B2i | Aug 13, 2024 | Press Releases

Alternative Proteins Entered into a development and commercialization partnership for the sale of animal-free recombinant albumin products with Proliant Health and BiologicalsEntered into a joint development agreement with a Top 10 global dairy company for the...

Dyadic to Report Second Quarter 2024 Financial Results on Tuesday, August 13, 2024

by B2i | Jul 30, 2024 | Press Releases

JUPITER, Fla., July 30, 2024 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...

Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

by B2i | Jun 28, 2024 | Press Releases

JUPITER, Fla., June 28, 2024 — Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of...